TABLE 2.
Population pharmacodynamic parameters derived from nonlinear mixed-effects modeling of the in vitro mefloquine susceptibility data
| Parametera | AFRIMSb | Wellcome Unit | SMRUc | All 415 strains |
|---|---|---|---|---|
| EC90 (ng/ml) | 51.08 (2.20)d | 49.00 (6.64) | 53.88 (7.49) | 50.43 (1.98) |
| 95% PI for EC90 (ng/ml) | 12.55–207.84 | 8.89–270.15 | 13.93–208.34 | 11.96–212.56 |
| γ | 2.44 (0.06) | 2.47 (0.18) | 3.19 (0.22) | 2.50 (0.06) |
| 95% PI for γ | 1.21–4.92 | 1.03–5.93 | 1.85–5.49 | 1.22–5.13 |
| Emax (%) | 102.30 (0.69) | 97.85 (1.59) | 103.96 (3.38) | 101.89 (0.64) |
| E0 (%) | −1.56 (0.46) | 0.36 (0.63) | 2.24 (0.69) | −0.76 (0.35) |
| ωECmax | 0.106 | 0.097 | 0.158 | 0.110 |
| ωEC90 | 0.716 | 0.871 | 0.690 | 0.734 |
| ωγ | 0.358 | 0.447 | 0.277 | 0.367 |
| ςɛ (% residual error) | 10.85 | 8.64 | 6.76 | 10.31 |
a
ωECmax, ωEC90, and ωγ, interstrain variability for Emax, EC90, and γ. PI, prediction interval.
b
AFRIMS, U.S. Armed Forces Research Institute of Medical Sciences.
c
SMRU, Shoklo Malaria Research Unit.
d
Standard errors are given in parentheses.